Importantly, we also found that dasatinib strongly inhibited BKS-2 lymphoma growth in vivo in a mouse lymphoma model (Fig. 7), making it potential drug to be tested in combination with current therapies like R-CHOP [55]. The gene discussed is DDIT3; the disease is lymphoma.